CDKN1B/p27 KIP 1 Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-0742R-FITC |
| Product Name | CDKN1B/p27 KIP 1 Polyclonal Antibody, FITC Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Sheep, Pig, Chicken |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CDKN1B |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1027 |
| Swiss Prot | P46527 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | KIP1; MEN4; CDKN4; MEN1B; P27KIP1; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; CDKN1B |
| Background | Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |